BETA: Please send your feedback!
MacroGenics
MGNX:NAS
Biotechnology
$555.42mm
SMALL cap
$11.36
(0.36%)
-0.10%
since start of 2019
-3.25
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 2
-
CF
-
PP
-
WC
-
DP
-
CH
-
ES
-
WS
-
CG
-
EP
-
CM
-
FL
-
GD
- —
- 1
- 2
- 3
- 4
- 5
About
Biotechnology
Founded 2000
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. It is focused on three therapeutic areas: Oncology, Autoimmune Disorders and Infectious Diseases. The company's proprietary technology platforms include Dual-Affinity Re-Targeting (DART) Therapeutics, which allow to incorporate multiple specificities within a single molecule; FC Optimization, enhances antibody-dependent functions; and Cancer Stem Cell, which provides a unique discovery tool to identify cancer targets shared by both tumor-initiating cells and differentiated cancer cells. Its infectious disease portfolio includes antibody-based therapeutics for the treatment of infectious diseases from pathogens, such as dengue, smallpox and H5N1. The company's autoimmune program, teplizumab, is an anti-CD3 antibody developed for the prevention and treatment of early onset diabetes. MacroGenics was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
website
Headquarters
Executives
| Name | Title | Gender |
| Leroy E. Hood, MD, PhD | Founder | Male |
| Scott E. Koenig, MD, PhD | President, Chief Executive Officer & Director | Male |
| Ezio Bonvini, MD | Chief Scientific Officer & Senior VP-Research | Male |
| Joseph Panigot | Vice President-Legal Affairs | Male |
| Robert Obst, MBA | Vice President-Human Resources & Facilities | Male |
| Lynn Cilinski | Treasurer, Vice President & Controller | Female |
| Ruedi Aebersold, PhD | Founder | Male |
| Alan Aderem, PhD | Founder | Male |
| Jeffrey V. Ravetch, MD, PhD | Founder | Male |
| Paulo F. Costa, MBA | Chairman | Male |
| James Karrels, MBA | Chief Financial Officer, Secretary & Senior VP | Male |
| Atul Saran | Senior Vice President & General Counsel | Male |
| Jon Wigginton, MD | Chief Medical Officer & SVP-Clinical Development | Male |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
-
Carbon Footprint — N/A
-
Pollution Prevention — N/A
-
Water Conservation — N/A
-
Data & Privacy Protection — N/A
-
Consumer Health, Wellness & Safety — N/A
-
Employee Ownership, Satisfaction, Benefits & Pay — N/A
-
Workplace Health and Safety — N/A
-
Integrity of Corporate Governance — N/A
-
Ethical Practices — N/A
-
Usage of Conflict Materials — N/A
-
Forced Labor — N/A
-
Diversity of Corporate Leadership 2
MacroGenics - Competitors and Related Companies
How MacroGenics stacks up to its peers in the Biotechnology industry or with competing business segments.
MacroGenics
MGNX:NAS
Biotechnology
$555.42mm
SMALL cap
$11.36
(0.36%)
-0.10%
since start of 2019
-3.25
Stemline Therapeutics
STML:NAS
Biotechnology
$408.13mm
SMALL cap
$9.29
(0.26%)
-0.06%
since start of 2019
-3.33
Xencor
XNCR:NAS
Biotechnology
$2.05bn
SMALL cap
$36.26
(1.18%)
0.01%
since start of 2019
41.67
Bristol-Myers Squibb
BMY:NYS
Pharmaceuticals: Major
$87.02bn
MEGA cap
$53.20
(0.17%)
0.01%
since start of 2019
13.96
Merck
MRK:NYS
Pharmaceuticals: Major
$216.40bn
MEGA cap
$84.52
(-0.16%)
0.12%
since start of 2019
23.49
Pfizer
PFE:NYS
Pharmaceuticals: Major
$201.66bn
MEGA cap
$36.46
(0.00%)
-0.16%
since start of 2019
16.35